. Author manuscript; available in PMC: 2025 Jun 17.

Published in final edited form as: Hepatology. 2024 May 31;80(6):1424–1440. doi: 10.1097/HEP.0000000000000935

TABLE 3.

Current trials of combination interventions

NCT number	Interventions	Phases
NCT05942963	Empagliflozin 10 mg \| pioglitazone 15 mg \| metformin NNC0194 0499 50 mg/mL \| placebo (NNC0194-0499) \| semaglutide 3 mg/mL \| semaglutide placebo \| NNC0174 0833 10 mg/mL \| NNC0174 0833 placebo	PHASE 4
NCT04976283	Pioglitazone \| empagliflozin \| pioglitazone + empagliflozin	PHASE 4
NCT04971785	Semaglutide \| cilofexor/firsocostat	PHASE 2
NCT05623189	HTD1801 \| placebo	PHASE 2
NCT04639414	Empagliflozin 10 mg oral tablet/semaglutide 1 mg pen injector \| empagliflozin 10 mg oral tablet and placebo\| Placebo	PHASE 4